Thai, Hong
Lara, James
Xu, Xiaojun
Kitrinos, Kathryn
Gaggar, Anuj
Chan, Henry Lik Yuen
Xia, Guo-liang
Ganova-Raeva, Lilia
Khudyakov, Yury
Article History
Received: 7 May 2020
Accepted: 2 September 2020
First Online: 23 September 2020
Competing interests
: H.T., J.L., X.X., G.X., L.G.-R. and Y.K. (Centers for Disease Control and Prevention) declare no competing interests. CDC Disclaimer: the findings and conclusions of this manuscript are those of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. K.K. was an employee and stockholder at Gilead Sciences at the time the work was completed. A.G. is an employee and stockholder at Gilead Sciences. H.L.Y.C. is an advisor of Abbvie, Aligos, Arbutus, Gilead Sciences, Intellia, Janssen, MedImmune, Merck, Roche, Vir Biotechnology, Vaccitech, VenatoRx; and a speaker for Gilead Sciences, Mylan and Roche.